CD38 and plasma cell myeloma: Relevant studies suggest that the mechanisms of multiple myeloma resistance to daratumumab are associated with immune escape (5), as relapsing patients show stable expression of unmutated CD38 on cancer cells, which preserves their ability to be targeted by daratumumab (6).